about
sameAs
The role of ultrasound in assessing musculoskeletal symptoms of systemic lupus erythematosus: a systematic literature reviewEfficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.Co-stimulatory blockade as therapy for rheumatoid arthritis.Development and Validation of the OMERACT Rheumatoid Arthritis Magnetic Resonance Tenosynovitis Scoring System in a Multireader Exercise.Rituximab: novel B-cell depletion therapy for the treatment of rheumatoid arthritis.Network Analysis Identifies Proinflammatory Plasma Cell Polarization for Secretion of ISG15 in Human Autoimmunity.The development of targeted therapies in rheumatoid arthritis.Costimulation blockade in rheumatic diseases: where we are?Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.Rituximab biosimilars.Biologics in systemic lupus erythematosus: current options and future perspectives.B Cell Therapies, Approved and Emerging: a Review of Infectious Risk and Prevention During Use.Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus.The prevalence of self-reported lower limb and foot health problems experienced by participants with systemic lupus erythematosus: Results of a UK national survey.Effect of rituximab on the progression of rheumatoid arthritis-related interstitial lung disease: 10 years' experience at a single centre.Patients' experiences of lupus-related foot problems: a qualitative investigation.Musculoskeletal manifestations of systemic lupus erythmatosus.The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales.IFNλ Stimulates MxA Production in Human Dermal Fibroblasts via a MAPK-Dependent STAT1-Independent Mechanism.Abatacept in the treatment of rheumatoid arthritis.Abatacept in the treatment of rheumatoid arthritis.Erratum to: Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis.Right drug, right patient, right time: aspiration or future promise for biologics in rheumatoid arthritis?An immunological biomarker to predict MTX response in early RA.Reduced-dose rituximab in rheumatoid arthritis: efficacy depends on degree of B cell depletion.Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis.Chylous ascites in a patient with an overlap syndrome: a surprising response to rituximab.The initiation of autoimmunity at epithelial surfaces: a focus on rheumatoid arthritis and systemic lupus erythematosus.A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features.Pharmacogenomics in rheumatoid arthritis: how close are we to the clinic?Choosing the right rituximab dose for the right patient: comment on the article by Bredemeier et al.Response to: 'Which B-cell subset should we target in lupus?' by Ferraccioli and Houssiau.Publisher Correction: A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical featuresDeterminants of response to B cell depletion in rheumatic diseasesResponsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosusPlasmacytoid dendritic cells are functionally exhausted while non-haematopoietic sources of type I interferon dominate human autoimmunity: Supplemental Figures and TablesEffect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasisValidity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosusAssessment of responsiveness of the musculoskeletal component of SLE-DAS in an independent cohort
P50
Q26786206-8E3E9D5C-8F66-4FA0-8113-F79531EE74FFQ34060110-CB354908-D9BC-4967-9434-AA08E72E61CBQ36262484-BA029B22-961E-4EF4-8B02-52BBEAD8909EQ36360142-F628E906-20A3-4AE4-A326-03C000074330Q36675413-0FBA5D1B-6D65-4A02-A5CB-56B671CEE9BCQ37153681-9873DCBB-B732-43CA-89B1-CD327EC3C8D9Q37172331-03F8EB0B-514A-440D-B761-EA23C2E4DF59Q37431437-F24DBFC0-1592-4479-9B05-C9610FD530F6Q37498738-EFB613D8-8677-4AD7-A650-8D057617371EQ38100232-AF34198F-0B76-4BD7-8B68-CECAFDCC3E1EQ38238798-DC3B94BB-A166-4975-8138-46FBEDC61D18Q38569860-0B5C98AD-0296-4B3D-A885-15C31F958131Q38690330-30B96EB1-B414-4F44-94BA-BE569CCA64EEQ38816264-FA46FF50-BFDF-4B0B-9CC0-7E6EBF3F1334Q38819214-03BC390E-B12D-4118-BC1D-159507C3C4EDQ38831837-9B558303-2CD2-403D-BB5D-514AC9C64B43Q39404958-D208D638-6D4D-4B98-9F90-BF1C12BCEB58Q40183925-49A685EA-50DC-4289-995A-EA9ADF882639Q40232762-4164B9A2-AE74-4BD7-AC79-76F4D974EA0CQ41470344-C1657DB9-6494-41DC-B2E0-D6DE0B15F768Q41905727-AAB12821-33A6-4085-A74A-A519D0437E15Q42128229-5ACF5A8C-C732-4F44-B8D0-2DE2A851FC3CQ42328583-0DD13005-46CF-4B63-A20F-A9A8A1CBD564Q42633541-46C7ABD4-1A11-455B-9306-7DA537823D51Q45830734-06682637-5719-43D5-8BD9-097FCFBB5A6EQ45929457-2C55B8CE-9099-4D11-90BA-827FA4406C02Q46343352-B5543D14-44F2-4156-B00F-02D24A2EAC11Q48153327-59ABA594-9FA9-4FA7-9C89-8811B0B2A108Q49572382-ae12b5eb-48c3-898d-db03-a0f121fcb9b8Q52593114-2E01137B-A6C1-4345-AD9B-7E03DC663DE3Q52839030-A4E0B0B9-E169-4E69-BAB5-10DA6625BED2Q52839527-47EB4027-0403-4F64-AC66-18ECD4D71E5AQ52840465-47E8914D-EE1F-4916-BE02-FBD845915CC2Q57062540-7F2E6A63-6BE5-494F-82AE-939AD3C18E7DQ58460520-0B1B798C-6840-4FDF-81FD-69604FC7602FQ61821116-1C2BCABC-01BF-48EF-A0F8-E13A1939ED9BQ61838620-9FEAC997-2119-42FB-A503-85F516D9957CQ89743252-AAA9BCBA-8285-4440-8C2F-5F0800203388Q90113222-22A52D64-E28D-4572-85AC-4CE44878FC23Q91521194-CBF408FA-9925-4871-B21E-A79CF099085A
P50
description
hulumtues
@sq
researcher
@en
researcher
@en-ca
researcher
@en-gb
wetenschapper
@nl
ymchwilydd
@cy
հետազոտող
@hy
name
Edward Marc John Vital
@de
Edward Marc John Vital
@en-ca
Edward Marc John Vital
@es
Edward Marc John Vital
@fr
Edward Marc John Vital
@it
Edward Marc Vital
@cy
Edward Marc Vital
@en
Edward Marc Vital
@en-gb
Edward Marc Vital
@nl
Edward Marc Vital
@sl
type
label
Edward Marc John Vital
@de
Edward Marc John Vital
@en-ca
Edward Marc John Vital
@es
Edward Marc John Vital
@fr
Edward Marc John Vital
@it
Edward Marc Vital
@cy
Edward Marc Vital
@en
Edward Marc Vital
@en-gb
Edward Marc Vital
@nl
Edward Marc Vital
@sl
altLabel
Edward M Vital
@cy
Edward M Vital
@en
Edward M Vital
@en-gb
Edward Marc John Vital
@cy
Edward Marc John Vital
@en
Edward Marc John Vital
@en-gb
Edward Marc John Vital
@nl
Edward Marc John Vital
@sl
Edward Vital
@cy
Edward Vital
@en
prefLabel
Edward Marc John Vital
@de
Edward Marc John Vital
@en-ca
Edward Marc John Vital
@es
Edward Marc John Vital
@fr
Edward Marc John Vital
@it
Edward Marc Vital
@cy
Edward Marc Vital
@en
Edward Marc Vital
@en-gb
Edward Marc Vital
@nl
Edward Marc Vital
@sl
P106
P1153
12772074400
P2031
2005-01-01T00:00:00Z
P21
P213
0000 0004 2745 7596
P31
P496
0000-0003-1637-4755